O	0	7	Effects
O	8	10	of
B-intervention	11	30	hydrochlorothiazide
O	31	33	on
B-condition	34	42	drainage
I-condition	43	49	volume
I-condition	50	53	and
I-condition	54	60	seroma
I-condition	61	70	formation
O	71	73	in
O	74	78	deep
O	79	87	inferior
O	88	98	epigastric
O	99	109	perforator
O	110	114	flap
O	115	121	breast
O	122	136	reconstruction
O	136	137	:
O	138	148	Randomized
O	149	159	controlled
O	160	165	trial
O	165	166	.

O	167	173	Seroma
O	174	176	is
O	177	178	a
O	179	189	recognized
O	190	202	complication
O	203	214	encountered
O	215	217	at
O	218	221	the
O	222	235	reconstructed
O	236	242	breast
O	243	246	and
O	247	252	donor
O	253	257	site
O	258	263	after
O	264	273	abdominal
O	273	274	-
O	274	279	based
O	280	286	breast
O	287	301	reconstruction
O	301	302	.

O	303	309	Seroma
O	310	312	is
O	313	319	caused
O	320	322	by
O	323	332	lymphatic
O	333	340	channel
O	341	351	disruption
O	352	355	and
O	356	359	the
O	360	369	formation
O	370	372	of
O	373	374	a
O	375	380	large
O	381	386	space
O	387	394	between
O	395	398	the
O	399	403	deep
O	404	410	fascia
O	411	417	during
O	418	422	flap
O	423	432	elevation
O	432	433	.

O	434	442	Surgical
O	443	453	techniques
O	454	456	to
O	457	465	preserve
O	466	469	the
O	470	480	lymphatics
O	481	484	and
O	485	491	secure
O	492	495	the
O	496	503	closure
O	504	506	of
O	507	510	the
O	511	516	donor
O	517	521	site
O	522	525	can
O	526	532	reduce
O	533	539	seroma
O	540	549	formation
O	549	550	.

O	551	555	This
O	556	561	study
O	562	574	investigated
O	575	578	the
O	579	585	safety
O	586	589	and
O	590	603	effectiveness
O	604	606	of
O	607	610	the
O	611	619	diuretic
O	620	639	hydrochlorothiazide
O	640	642	at
O	643	651	reducing
O	652	664	interstitial
O	665	670	fluid
O	671	683	accumulation
O	684	687	and
O	688	694	seroma
O	695	704	formation
O	705	711	during
O	712	716	deep
O	717	725	inferior
O	726	736	epigastric
O	737	747	perforator
O	748	749	(
O	749	753	DIEP
O	753	754	)
O	755	759	flap
O	760	766	breast
O	767	781	reconstruction
O	781	782	.

B-total-participants	783	788	Sixty
B-eligibility	789	797	patients
I-eligibility	798	802	with
I-eligibility	803	809	breast
I-eligibility	810	816	cancer
I-eligibility	817	820	who
I-eligibility	821	830	underwent
I-eligibility	831	835	skin
I-eligibility	835	836	-
I-eligibility	837	839	or
I-eligibility	840	846	nipple
I-eligibility	846	847	-
I-eligibility	847	854	sparing
I-eligibility	855	865	mastectomy
I-eligibility	866	869	and
I-eligibility	870	874	DIEP
I-eligibility	875	879	flap
I-eligibility	880	894	reconstruction
O	895	899	were
O	900	908	enrolled
O	909	916	between
O	917	923	August
O	924	928	2016
O	929	932	and
O	933	937	June
O	938	942	2017
O	942	943	.

O	944	947	The
O	948	956	patients
O	957	961	were
O	962	970	randomly
O	971	979	assigned
O	980	982	to
O	983	990	receive
O	991	997	either
O	998	1000	25
O	1001	1003	mg
O	1004	1007	per
O	1008	1011	day
O	1012	1014	of
O	1015	1034	hydrochlorothiazide
O	1035	1039	from
O	1040	1043	the
O	1044	1050	second
O	1051	1053	to
O	1054	1057	the
O	1058	1067	twentieth
O	1068	1071	day
O	1072	1077	after
O	1078	1085	surgery
O	1086	1087	(
O	1087	1096	treatment
O	1096	1097	)
O	1098	1100	or
B-control	1101	1103	no
I-control	1104	1112	diuretic
I-control	1113	1114	(
I-control	1114	1121	control
I-control	1121	1122	)
O	1122	1123	.

O	1124	1127	The
O	1128	1147	clinicopathological
O	1148	1163	characteristics
O	1163	1164	,
O	1165	1173	drainage
O	1174	1178	time
O	1178	1179	,
O	1180	1183	and
O	1184	1192	drainage
O	1193	1199	volume
O	1200	1204	were
O	1205	1218	statistically
O	1219	1227	compared
O	1228	1235	between
O	1236	1239	the
O	1240	1243	two
O	1244	1250	groups
O	1250	1251	.

O	1252	1255	The
B-outcome	1256	1263	average
I-outcome	1264	1269	total
I-outcome	1270	1278	drainage
I-outcome	1279	1285	volume
I-outcome	1286	1288	at
I-outcome	1289	1292	the
I-outcome	1293	1298	donor
I-outcome	1299	1303	site
O	1304	1307	was
B-iv-cont-mean	1308	1311	291
I-iv-cont-mean	1312	1314	mL
O	1315	1317	in
O	1318	1321	the
O	1322	1331	treatment
O	1332	1337	group
O	1338	1341	and
B-cv-cont-mean	1342	1345	434
I-cv-cont-mean	1346	1348	mL
O	1349	1351	in
O	1352	1355	the
O	1356	1363	control
O	1364	1369	group
O	1370	1371	(
O	1371	1372	p
O	1373	1374	=
O	1375	1376	0
O	1376	1377	.
O	1377	1380	003
O	1380	1381	)
O	1381	1382	.

O	1383	1386	The
O	1387	1398	differences
O	1399	1401	in
B-outcome	1402	1406	body
I-outcome	1407	1411	mass
I-outcome	1412	1417	index
O	1418	1421	and
B-outcome	1422	1426	flap
I-outcome	1427	1433	weight
O	1434	1441	between
O	1442	1445	the
O	1446	1449	two
O	1450	1456	groups
O	1457	1461	were
O	1462	1465	not
O	1466	1479	statistically
O	1480	1491	significant
O	1492	1493	(
O	1493	1494	p
O	1495	1496	=
O	1497	1498	0
O	1498	1499	.
O	1499	1502	879
O	1503	1506	and
O	1507	1508	p
O	1509	1510	=
O	1511	1512	0
O	1512	1513	.
O	1513	1516	963
O	1516	1517	,
O	1518	1530	respectively
O	1530	1531	)
O	1531	1532	.

B-outcome	1533	1535	No
I-outcome	1536	1547	hypotension
I-outcome	1548	1550	or
I-outcome	1551	1562	electrolyte
I-outcome	1563	1572	imbalance
O	1573	1576	was
O	1577	1582	noted
O	1583	1589	during
O	1590	1593	the
O	1594	1600	follow
O	1600	1601	-
O	1601	1603	up
O	1603	1604	.

O	1605	1611	Intake
O	1612	1614	of
O	1615	1617	25
O	1618	1620	mg
O	1621	1624	per
O	1625	1628	day
O	1629	1631	of
O	1632	1651	hydrochlorothiazide
O	1652	1659	tablets
O	1660	1671	effectively
O	1672	1679	reduced
O	1680	1683	the
O	1684	1689	total
O	1690	1699	abdominal
O	1700	1708	drainage
O	1709	1715	volume
O	1716	1719	and
O	1720	1727	removal
O	1728	1732	time
O	1733	1735	of
O	1736	1746	indwelling
O	1747	1753	drains
O	1753	1754	.

O	1755	1762	However
O	1762	1763	,
O	1764	1767	the
O	1768	1775	adverse
O	1776	1783	effects
O	1784	1790	should
O	1791	1793	be
O	1794	1801	further
O	1802	1814	investigated
O	1815	1817	in
O	1818	1819	a
O	1820	1825	large
O	1826	1836	population
O	1837	1840	and
O	1841	1852	multiracial
O	1853	1859	cohort
O	1860	1866	before
O	1867	1872	using
O	1873	1892	hydrochlorothiazide
O	1893	1896	for
O	1897	1903	seroma
O	1904	1914	prevention
O	1914	1915	.
